MENU
+Compare
LGND
Stock ticker: NASDAQ
AS OF
Jun 27 closing price
Price
$114.15
Change
-$1.54 (-1.33%)
Capitalization
2.2B

LGND Ligand Pharmaceuticals Forecast, Technical & Fundamental Analysis

Ligand Pharmaceuticals Inc is a biopharmaceutical company focused on developing and acquiring technologies that aid in creating medicine... Show more

Industry: #Biotechnology
LGND
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
Interact to see
Advertisement
A.I.Advisor
a Summary for LGND with price predictions
Jun 27, 2025

LGND in upward trend: price rose above 50-day moving average on June 06, 2025

LGND moved above its 50-day moving average on June 06, 2025 date and that indicates a change from a downward trend to an upward trend. In of 34 similar past instances, the stock price increased further within the following month. The odds of a continued upward trend are .

Price Prediction Chart

Technical Analysis (Indicators)

Bullish Trend Analysis

The Moving Average Convergence Divergence (MACD) for LGND just turned positive on June 04, 2025. Looking at past instances where LGND's MACD turned positive, the stock continued to rise in of 45 cases over the following month. The odds of a continued upward trend are .

The 10-day moving average for LGND crossed bullishly above the 50-day moving average on June 11, 2025. This indicates that the trend has shifted higher and could be considered a buy signal. In of 16 past instances when the 10-day crossed above the 50-day, the stock continued to move higher over the following month. The odds of a continued upward trend are .

Following a 3-day Advance, the price is estimated to grow further. Considering data from situations where LGND advanced for three days, in of 317 cases, the price rose further within the following month. The odds of a continued upward trend are .

Bearish Trend Analysis

The 10-day RSI Indicator for LGND moved out of overbought territory on June 25, 2025. This could be a bearish sign for the stock. Traders may want to consider selling the stock or buying put options. Tickeron's A.I.dvisor looked at 31 similar instances where the indicator moved out of overbought territory. In of the 31 cases, the stock moved lower in the following days. This puts the odds of a move lower at .

The Stochastic Oscillator may be shifting from an upward trend to a downward trend. In of 57 cases where LGND's Stochastic Oscillator exited the overbought zone, the price fell further within the following month. The odds of a continued downward trend are .

The Momentum Indicator moved below the 0 level on June 27, 2025. You may want to consider selling the stock, shorting the stock, or exploring put options on LGND as a result. In of 81 cases where the Momentum Indicator fell below 0, the stock fell further within the subsequent month. The odds of a continued downward trend are .

Following a 3-day decline, the stock is projected to fall further. Considering past instances where LGND declined for three days, the price rose further in of 62 cases within the following month. The odds of a continued downward trend are .

LGND broke above its upper Bollinger Band on June 09, 2025. This could be a sign that the stock is set to drop as the stock moves back below the upper band and toward the middle band. You may want to consider selling the stock or exploring put options.

The Aroon Indicator for LGND entered a downward trend on June 09, 2025. This could indicate a strong downward move is ahead for the stock. Traders may want to consider selling the stock or buying put options.

Fundamental Analysis (Ratings)

The Tickeron Price Growth Rating for this company is (best 1 - 100 worst), indicating steady price growth. LGND’s price grows at a higher rate over the last 12 months as compared to S&P 500 index constituents.

The Tickeron Seasonality Score of (best 1 - 100 worst) indicates that the company is fair valued in the industry. The Tickeron Seasonality score describes the variance of predictable price changes around the same period every calendar year. These changes can be tied to a specific month, quarter, holiday or vacation period, as well as a meteorological or growing season.

The Tickeron Profit vs. Risk Rating rating for this company is (best 1 - 100 worst), indicating well-balanced risk and returns. The average Profit vs. Risk Rating rating for the industry is 95, placing this stock slightly better than average.

The Tickeron Valuation Rating of (best 1 - 100 worst) indicates that the company is slightly overvalued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (2.769) is normal, around the industry mean (16.366). P/E Ratio (46.189) is within average values for comparable stocks, (58.189). LGND's Projected Growth (PEG Ratio) (0.000) is slightly lower than the industry average of (2.309). Dividend Yield (0.000) settles around the average of (0.041) among similar stocks. P/S Ratio (11.737) is also within normal values, averaging (252.247).

The Tickeron PE Growth Rating for this company is (best 1 - 100 worst), pointing to worse than average earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.

The Tickeron SMR rating for this company is (best 1 - 100 worst), indicating weak sales and an unprofitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.

View a ticker or compare two or three
LGND
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
Interact to see
Advertisement
A.I. Advisor
published Earnings

LGND is expected to report earnings to rise 7.52% to $1.43 per share on August 11

Ligand Pharmaceuticals LGND Stock Earnings Reports
Q2'25
Est.
$1.43
Q1'25
Beat
by $0.11
Q4'24
Beat
by $0.09
Q3'24
Beat
by $0.50
Q2'24
Beat
by $0.34
The last earnings report on May 08 showed earnings per share of $1.33, beating the estimate of $1.22. With 327.87K shares outstanding, the current market capitalization sits at 2.20B.
A.I.Advisor
published Dividends

LGND paid dividends on July 01, 2010

Ligand Pharmaceuticals LGND Stock Dividends
А quarterly dividend of $0.12 per share was paid with a record date of July 01, 2010, and an ex-dividend date of July 02, 2010. Read more...
A.I. Advisor
published General Information

General Information

a biotechnology company

Industry Biotechnology

Profile
Fundamentals
Details
Industry
Biotechnology
Address
555 Heritage Drive
Phone
+1 858 550-7500
Employees
58
Web
https://www.ligand.com
Interesting Tickers
1D
1W
1M
1Q
6M
1Y
5Y
1 Day
MFs / NAMEPrice $Chg $Chg %
FCIWX17.590.21
+1.21%
NYLI PineStone International Eq Cl R6
CIUEX13.030.13
+1.01%
Six Circles International Uncon Eq
MEERX8.140.07
+0.87%
MassMutual International Eq R3
OGINX46.370.33
+0.72%
Invesco Global Opportunities R
EARAX14.990.03
+0.20%
Eaton Vance RBA All Asset Strategy Fd A

LGND and Stocks

Correlation & Price change

A.I.dvisor indicates that over the last year, LGND has been loosely correlated with ACLX. These tickers have moved in lockstep 48% of the time. This A.I.-generated data suggests there is some statistical probability that if LGND jumps, then ACLX could also see price increases.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To LGND
1D Price
Change %
LGND100%
-1.33%
ACLX - LGND
48%
Loosely correlated
+0.90%
CRNX - LGND
47%
Loosely correlated
-0.10%
ROIV - LGND
47%
Loosely correlated
-1.81%
CRSP - LGND
47%
Loosely correlated
N/A
DNLI - LGND
46%
Loosely correlated
-2.69%
More